why gbi will deliver 10x returns over 12 mths, page-9

http://www.biospectrumasia.com/Content/230908OTH7164.asp

Qiagen do not intend to cannibalise their HC2 franchise in the developed world with this test.

It seems to me that it is a test that is much "better than nothing" for areas with poor healthcare infrastructure, but no intention to compete with HC2 / Third Wave / PapType etc.

It would be a competitor of the test that China Med Tech paid US$345m for a few weeks back. . ..